



active pharmaceutical ingredients*	
Commercial Scale	
Antitubercular	Macrolides
Pyrazinamide [#]	Azithromycin
Isoniazid [#]	Clarithromycin
Antimalarial	Erythromycin base [#]
Artesunate	Erythromycin estolate [#]
Arteether	Erythromycin ethyl succinate ⁺
Artemether ⁺	Erythromycin oxime (intermediate)
Dihydroartemisinin	Erythromycin stearate [#]
Lumefantrine ⁺	Antiepileptic
Antihypertensive	Valproic acid [#]
Irbesartan ⁺	Sedative, Hypnotic
Losartan potassium [#]	Zopiclone [#]
Telmisartan	Antidepressant
Antihistaminic	Venlafaxine hydrochloride
Cetirizine dihydrochloride [#]	Antiosteoporotic
Meclizine dihydrochloride ⁺	Alendronate sodium
Hydroxyzine dihydrochloride ⁺	Zoledronic acid
Antifungal	
Flucytosine [#]	
intermediates	therapeutic category
Pilot Plant	
Clopidogrel bisulphate	Antithrombotic
Divalproex sodium ⁺	Antiepileptic
Eprosartan	Antihypertensive
Eszopiclone ⁺	Hypnotic
Piperaquine	Antimalarial
Valsartan	Antihypertensive
R & D Scale	
Atorvastatin calcium	Lipid Lowering Agent
Desvenlafaxine succinate ⁺	Antidepressant
Development	
Famciclovir	Antiretroviral
Ganciclovir	Antiretroviral
Levocetirizine	Antihistaminic
Valganciclovir	Antiretroviral

US DMF / EU CoS / Russian Registration

+ CTD filing under process

*The Technical and Physical manufacturing capabilities exist with us for the above APIs and their intermediates. However these products will be offered only to the markets where any product or process patents are not infringing. During the validity of a patent the research quantities for developing products for regulatory submissions will only be offered to countries where such exemption exists (Hatch Waxman Act / Bolar exemption). While Calyx offers to work with the clients on Patent Status Verification, the final responsibility vests with the buyer. Recipients are requested to make their evaluation and determination as to the patent status prior to their use of the information or materials in their respective jurisdiction. Products under patent offered only for exempted research, clinical and development purposes. Only non-infringing products and processes are offered, subject to patent status verification by client.

Calyx Chemicals & Pharmaceuticals Limited

Regd. Office: Unit No.2, Marwah's Complex, Marwah Estate, Saki Vihar Road, Andheri (E), Mumbai 400072, India.

Tel: +91-22-28571191, Fax: +91-22-66466817

Corp. Office: A 37/38, MIDC Phase 1, Golavli, Kalyan Shil Road, Dombivli (E), Dist. Thane 421203, India. Tel: +91-251-6698300

Fax: +91-251-2438726. Fax: +91-22-66466401

Los Angeles: Tel: +1-213-291-7773

Email: sales@calyxindia.com, crams@calyxindia.com, sales@calyxusa.com, crams@calyxusa.com, www.calyxindia.com

Disclaimer:

Calyx Chemicals and Pharmaceuticals Limited (the "Company") is proposing to make, subject to receipt of requisite approvals, market conditions and other considerations, an Initial Public Offering of its equity shares (the "IPO") and intends to file a Draft Red Herring Prospectus (the "DRHP") with the Securities and Exchange Board of India ("SEBI"). The DRHP, after the same is filed with SEBI, will be available on the website of SEBI at www.sebi.gov.in, the website of the BRLM at www.plindia.com and the website of the Company at www.calyx-pharma.com. Potential investors should note that investment in equity shares involves a high degree of risk. For details, please refer to and rely on the DRHP, including the section titled "Risk Factors" of the DRHP. This publicity material does not constitute an offer of securities in any jurisdiction, including the United States of America ("USA"). Securities may not be offered or sold in the USA without registration under the U.S. Securities Act of 1933 as amended, or an exemption therefrom. The Company has not and does not intend to offer any securities to the public in the USA.